Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
F. Shepherd (Toronto, Canada). Unresolved issues in the use of check-point inhibitors in NSCLC. ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?

Member's Comments

No comment yet.

Related content which might interest you: Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 What specific issues arise in the management of elderly patients with advanced NSCLC? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 The role of robotics in the treatment of NSCLC Source: International Congress 2015 – Robotics in pulmonology and thoracic surgery Year: 2015 Lung cancer screening: latest developments and unanswered questions Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 The role of the EGFR-pathway and angiogenesis in lung cancer: basic considerations Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Practical considerations for therapies targeting the prostacyclin pathway Source: Eur Respir Rev 2016; 25: 418-430 Year: 2016 TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011 Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues Source: Eur Respir J, 50 (2) 1701319; 10.1183/13993003.01319-2017 Year: 2017 Relapsed NSCLC and SCLC: benefits and limitations of systemic treatments beyond the second line Source: International Congress 2017 – Rational strategies for specific treatment situations in lung cancer Year: 2017 Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015 NSCLC management Source: ERS Course 2019 - Summer school of adult respiratory medicine Year: 2019 NSCLC management Source: ERS Course 2018 - Summer school of adult respiratory medicine Year: 2018 NSCLC management Source: ERS Skills Course 2017 - Summer school of adult respiratory medicine Year: 2017 NSCLC management Source: ERS Skills Course 2016 Year: 2016